Abstract
Six psychotic patients were included in a four-week study of the effects of the D1 selective antagonist SCH 39166 given as monotherapy. Four had a diagnosis of schizophrenia, and two suffered from a schizoaffective disorder. All presented with an acute psychotic exacerbation at the beginning of the trial. SCH 39166 was progressively increased from 50 mg/day to 600 mg/day. In the four schizophrenic patients, the BPRS worsened, and three out of the four failed to complete the study because of this. Three schizophrenic patients were aggressive or violent after abrupt discontinuation of treatment. In the two patients with schizoaffective disorder the BPRS improved during the trial, but they had an acute relapse immediately after treatment discontinuation. Extrapyramidal symptoms improved in three of the six patients, and worsened in one.
Similar content being viewed by others
References
Chipkin RE (1990) D1 antagonist in clinical trial. Trends Pharmacol Sci 11:185
Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D1 selective benzonaphtazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102
Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87
Duffy RA, Kaminska G, Chipkin RE, McQuade RD (1991) Selective up-regulation of D1 dopamine receptors following chronic administration of SCH 39166 in primates. Pharmacol Biochem Behav 28:477–482
Halldin C, Farde L, Barnett A, Sedvall G (1991) Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D1 receptor ligand, and preliminary PET investigations. Int J Rad Appl Instrum-A 42:451–455
Hyttel J, Arnt J, Van Den Berghe M (1989) Selective D1 and D2 antagonists. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry (Psychopharmacology series, vol. 7). Springer, Berlin Heidelberg New York, pp 109–122
Lappalainen J, Hietala J, Pohjalaninen T, SyvŠlahti E (1992) Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol 210:195–200
Laruelle M, Jaskiw GE, Lipska BK, Kolachana B, Casanova MF, Kleinman JE, Weinberger DR (1992) D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res 575:47–56
McQuade RD, Duffy RA, Coffin VL, Barnett A (1992) In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur J Pharmacol 215:29–34
Parsa MA, Al Lahhah YH, Ramirez LF, Meltzer HY (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 13:154–155
Prinssen EPM, Ellenbroek BA, Stamatovic B, Cools AR (1993) The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166. Eur J Pharmacol 231:275–280
Sedvall G, Farde L, Barnett A, Hall H, Halldin C (1991) 11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. Psychopharmacol 103:150–153
Tedford CE, Crosby G Jr, Iorio LC, Chipkin RE (1992) Effect of SCH 39166, a novel D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices. Eur J Pharmacol 211:169–176
Trabucci M, Andreoli VM, Frattola L, Spano PF (1977) Pre-and postsynaptic action of bromocriptine: its pharmacological effects in schizophrenia and neurological diseases. Adv Biochem Psychopharmacology 16:661–665
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Beaurepaire, R., Labelle, A., Jones, B.D. et al. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121, 323–327 (1995). https://doi.org/10.1007/BF02246070
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246070